

# Christian Gaebler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1098730/christian-gaebler-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

6,997  
citations

30  
h-index

64  
g-index

64  
ext. papers

10,762  
ext. citations

28.2  
avg, IF

6.18  
L-index

#	Paper	IF	Citations
51	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	1
50	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. <b>2022</b> ,		1
49	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. <b>2022</b> ,		3
48	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , <b>2022</b> ,	32.3	10
47	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , <b>2022</b> ,	50.4	14
46	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	93
45	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. <b>2021</b> ,		31
44	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , <b>2021</b> ,	50.4	69
43	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	3
42	Evolution of Antibody Immunity to SARS-CoV-2 <b>2021</b> ,		43
41	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies <b>2021</b> ,		24
40	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies <b>2021</b> ,		27
39	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 1249-1258	5.5	5
38	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year <b>2021</b> ,		19
37	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , <b>2021</b> , 595, 426-431	50.4	247
36	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2212-2218	59.2	347
35	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , <b>2021</b> , 12, 4196	17.4	106

34	COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research. <i>Current Opinion in HIV and AIDS</i> , <b>2021</b> , 16, 25-35	4.2	4
33	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	178
32	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , <b>2021</b> , 591, 639-644	50.4	652
31	Persistent cellular immunity to SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	59
30	TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability <b>2021</b> ,		2
29	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , <b>2021</b> , 592, 616-622	50.4	730
28	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York <b>2021</b> ,		54
27	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , <b>2021</b> , 95,	6.6	11
26	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , <b>2021</b> , 12, 4886	17.4	30
25	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , <b>2021</b> , 54, 1853-1868.e7	32.3	83
24	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , <b>2021</b> ,	50.4	65
23	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants <b>2021</b> ,		54
22	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , <b>2020</b> , 182, 828-842.e16	56.2	485
21	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , <b>2020</b> , 9,	8.9	784
20	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals <b>2020</b> ,		60
19	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies <b>2020</b> ,		30
18	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses <b>2020</b> ,		35
17	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants <b>2020</b> ,		32

16	Enhanced SARS-CoV-2 Neutralization by Secretary IgA in vitro <b>2020</b> ,		15
15	Persistent Cellular Immunity to SARS-CoV-2 Infection <b>2020</b> ,		9
14	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100123	18	46
13	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , <b>2020</b> , 584, 437-442	50.4	1167
12	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	289
11	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	34
10	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , <b>2020</b> , 26, 1339-1350	50.5	43
9	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 2253-2264	16.6	42
8	Engineered extracellular matrix components do not alter the immunomodulatory properties of mesenchymal stromal cells in vitro. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , <b>2013</b> , 7, 921-4	4.4	3
7	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160 $\beta$ (BaL.). <i>Journal of Immunological Methods</i> , <b>2013</b> , 397, 47-54	2.5	8
6	Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. <i>Cell</i> , <b>2013</b> , 153, 126-38	56.2	376
5	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. <i>Nature</i> , <b>2012</b> , 492, 118-22	50.4	401
4	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1469-79	16.6	131
3	Antigen responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir		3
2	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
1	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7